<DOC>
	<DOCNO>NCT00292461</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety zonisamide anti-epilepsy drug ( AEDs ) treat subject refractory simple partial , complex partial partial secondary generalize seizure .</brief_summary>
	<brief_title>A Study Evaluating Efficacy Safety Zonisamide Lamotrigine ( Lamictal ) Subjects With Refractory Simple Partial , Complex Partial Partial With Secondary Generalized Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Inclusion criterion : Subjects must sign date inform consent form Clinical diagnosis refractory epilepsy Exclusion criterion : Progressive neurologic disease Serious psychiatric disease Hemolytic anemia G6PD ( glucose6phosphate dehydrogenase ) deficiency Acute intermittent porphyria Subjects receive study drug ( Zonisamide , Lamotrigine ) past Drug alcohol addiction Renal impairment ( serum creatinine â‰§ 1.5 mg/dl ) , hepatic abnormality ( ALT AST &gt; 2x ULN ) StevensJohnson syndrome Progressive exfoliative dermatitis Pregnant , lactate childbearing potential female Regularly take oral contraceptive Hypersensitivity study drug Severe cardiac disease ( New York Heart Association Functional Class III IV ) History malignancy within 5 year Taking valproic acid within 7 day prior screen Subjects simple partial seizure without motor component</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>seizure</keyword>
</DOC>